FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome / Endpoints

Ayisha Sharma / endpoints - Corcept Therapeutics failed to secure US approval for its drug candidate as a hormonal disorder treatment. The FDA rejected Corcept’s selective cortisol modulator relacorilant for Cushing’s syndrome, according to a company

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

---

Monday, January 5, 2026, 1:21 am / permalink 17484 / 2 stories in 2 months

Related Stories

---

• FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 5 wks
• FDA approves Rucaparib for advanced prostate cancer / 2 months
• FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 2 months
• FDA Approves Novartis’ Itvisma Gene Therapy for SMA Across Age Groups / 3 months
• FDA Approves Ziftomenib for AML Treatment / 3 months
• FDA updates Sarepta gene therapy label with severe warnings / 3 months
• Experimental therapy reduces seizures in children with Dravet syndrome / 5 days

Related Tags

---

StackHealth Time Machine

---